Assessment v1
---------------------------------------------------------------------------------- # Atrial Fibrillation - Rate control (*** bpm): *** - Anticoagulation ***lovenox, heparin, coumadin - Need for cardioversion *** - CHADS2 score = CHF 1 Hypertension 1 Age> 75 y.o 1 Diabetes 1 Stroke/TIA 2 Score 0 associated with 1.9% stroke risk. Score 1 associated with 2.8% stroke risk. Score 2 associated with 4.0% stroke risk. Score 3 associated with 5.9% stroke risk. Score 4 associated with 8.5% stroke risk. Score 5 associated with 12.5% stroke risk. Score 6 associated with 18.2% stroke risk ---------------------------------------------------------------------------------- # TIA Description: The ABCD2 scoring system for assessing stroke risk after a TIA (transient ischemic attack); formatted as an Epic Smart Phrase. Stroke risk after transient ischemic attack. A. Age > 60 years = +1 B. Blood pressure > 140/90 mmHg: +1 for hypertension at presentation C. Clinical features including unilateral weakness (+2), speech disturbance without weakness (+1) D. Duration of TIA between10–59 minutes (+1), >60 minutes (+2). D. Diabetes (+1). Stroke risk at 2, 7 and 90 days 0-3: low risk 4-5: moderate risk 6-7: high risk Not that stroke risk is independent of mechanism whether cardioembolic, a watershed infarct, lacunar infarct, or other mechanism. References 1. Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JN, Warlow CP, Mehta Z. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005 Jul 2-8;366(9479):29-36. 2. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007 Jan 27;369(9558):283-92. ---------------------------------------------------------------------------------- # Altered Mental Status Hypoxia vs. Infection vs. TIA/stroke vs. Metabolic/Toxic. Dementia an unlikely cause given rapidity of onset. Hypoxia: ED O2 sat showed *** Continuous O2 NC and pulse ox - maintain O2 sat > 95% CXR shows: ***PNA, effusion, COPD, edema PE risk, Wells score: ***clinically suspected DVT - 3 points ***alternative diagnosis is less likely than PE - 3.0 points ***tachycardia - 1.5 points ***immobilization/surgery in previous four weeks - 1.5 points ***history of DVT or PE - 1.5 points ***hemoptysis - 1.0 points ***malignancy (treatment for within 6 months, palliative) - 1.0 points Interpretation (Stein et al. 2007 Radiology 242:15-21) Score >6.0 - High (probability 59% based on pooled data) Score 2.0 to 6.0 - Moderate (probability 29% based on pooled data) Score <2.0 - Low (probability 15% based on pooled data) Infection: *** of 4 SIRS criteria: @BRIEFLAB(WBC)@, *** left shift, *** HR, *** RR, @TMAX(24)@ UA w/ reflex culture *** Blood cultures x2 *** CXR shows*** Physical exam findings ***not suggestive of meningitis: *** ***Season ***not appropriate to West Nile TIA/stroke History of TIA/CVA *** *** focal findings on physical exam ***No early signs of stroke on Head CT, ***no hemorrhage or acute findings. AMS started ***; in***out of TPA window. ***Permissive HTN ***Carotid dopplers ***MRA Brain MRI*** ***EEG Metabolic Electrolytes *** TSH *** New medicines *** Recently stopped medicines *** Tox screen *** ---------------------------------------------------------------------------------- # Acetaminophen ingestion treatment (Prescott Protocol) GI decontamination Activated charcoal Antidote: N-acetylcysteine (NAC; Acetadote) for prophylaxis/prevention of acetaminophen-induced hepatic injury. NAC Loading Dose: 150 mg/kg in 200 mL of 5% dextrose, infuse intravenously over 60 minutes. NAC Maintenance Dose: First 4 hours: 50 mg/kg in 500 mL of 5% dextrose, infuse intravenously over 4 hours Followed by 100 mg/kg in 1000 mL of 5% dextrose, infuse intravenously over 16 hours Refs: Daly et al, 2008; Prod Info ACETADOTE(R) IV injection, 2006; Prescott et al, 1979. Monitor Acetaminophen levels Q12hr. Initial Acetaminophen level ***. Monitor LFTs Q12hr. Initial hepatic enzymes: ALT ***, AST *** Continue NAC therapy until serum acetaminophen concentration is undetectable and liver function improves (Smith et al, 2008). ---------------------------------------------------------------------------------- # Dyspnea Differential diagnosis include CHF, PE, pneumothorax, pneumonia, obstructive airway disease (COPD, asthma), restrictive airway disease, neuromuscular disorder, anemia Evaluation - O2 sat @FLO(2078:last)@ on *** O2 - exam significant for RR=***, accessory muscles used/not used***, pulmuonary exam shows *** - CHF history ***neg/pos with BNP of ***, S3***, - DVT/PE risk factors (pregnancy, cancer, hormone therapy, previous DVT, immobility, recent surgery/injury, family history of DVT, inherited hypercoagulability, obesity, age>60, very tall, smoking, calf pain) - COPD history: PFTs***, smoking history***, physical exam (barrel chested, wheezes)*** - Anemia: exam findings: pallor, tachycardia, flow murmur*** - Neuromuscular disease: neuro exam shows *** Plan - CXR: PA/Lateral *** - ECG *** - BNP *** - echocardiogram *** - CT PE protocol *** - Lower extremity dopplers *** - ABG *** - Pulmonary function tests *** - tele *** - DVT prophylaxis *** - DuoNebs *** - Daily CBC/BMG - Strict I&O, dailyl weights ---------------------------------------------------------------------------------- # # # [ Dizziness / Presyncope] # # # DDx includes orthostatic hypotension, cardiac source, vestibular disorders, , anxiety/depression, medication induced. Evaluation plan: Orthostatic hypotension - Check orthostatic vital signs; IVF if orthostatic - CBC/BMG - Daily weights Cardiac source: History of ***arrythmia ***aortic stenosis, and physical exam shows ***irregularly irregular rhythm, ***bradycardia, ***tachycardia, ***murmur suggesting cardiac source to pre-syncope - ECG - Telemetry - Echocardiogram Migraine: History of ***headache, photophobia, visual aura or changes, and previous migraines suggest migraine possible source. CNS disorder: History of ***atrial fibrillation (CHADS2 score) on***not on coumadin, ***previous CVA, ***seizure disorder, with neuro exam findings of ***, suggest a neuro origin to dizziness. - EEG - Head CT - If Head CT negative for bleed, permissive hypertension, daily aspirin - Frequent neuro checks Vestibular disorders: Vertigo (sensation of movement while sationary) suggests of vestibular source. History of ***brief (less than 30 s) dizziness with head movement in one direction and no tinnitus consistent with BPPV ***prolonged (longer than 30 s) dizziness, tinnitus, and nausea that has been happening for more than 2 weeks consistent with Meniere's disease ***prolonged (longer than 30 s) dizziness for less than 2 weeks and a recent URI consistent with viral vestibulitis or labyrinthitis ***worsening dizziness, hearing loss, tinitus, papilledema, other cranial nerve deficits (esp CN 7, 9/10) concerning for vestibular schwannoma (AKA acoustic neuroma). - Otoscopic exam shows *** - Ophthalmoscopic exam shows ***yes/no papilledema - ***Dix-Hallpike test for BPV - ***If hearing loss or tinnitus: Audiology testing - ***If concern for schwannoma or Meniere's disease: Brain MRI with thin slices through posterior fossa Anxiety/depression: History of *** suggests anxiety/depression as a contributing factor. Medication: Recent medication addition/change of *** ---------------------------------------------------------------------------------- # # # [ Syncope ] # # # Evaluating cardiac, neurological, and metabolic syncope Cardiovascular syncope: Differential diagnosis includes mechanical, electrical, vasovagal, orthostatic Cardiac mechanical (Aortic Stenosis, Hypertrophic cardiomyopathy, Pulmonary Embolism, HTN, Stenosis, Aortic Dissection, Myocardial Infarction) Plan: - Echo - CXR - D-dimer / CT-PE if hypoxic - EKG - CMx2; stress test if negative - EKG PRN with pain - Continuous pulse-ox - tele Cardiac electrical (AV Block, Sick Sinus Syndrome, Arrhythmia, Long QT syndrome) - EKG - tele Vasovagal Syncope (Carotid sinus cardioinhibitory, vasodepressor central, Vasovagal cough, micturition defecation, post-prandial valsalva, sneeze) Orthostatic (Dehydration, Diuretic drugs, Blood Loss, Autonomic insufficiency, Sympathetic nervous system blocker drugs, Adrenal Insufficiency, Vasodilator drugs, Idiopathic) Plan: - Measure orthostatic VS - Daily CBC/BMG - Review drugs Neurologic syncope: cerebral hypoperfusion due to Transient Ischemic Attack (TIA), Seizure, Takayatsu Arteritis, Intermittent Pressure Hydrocephalus, Subclavian Steel Syndrome, Vertebrobasilar insufficiency. Plan - Head CT - EEG - MRI/MRA - Cardiac echo - Carotid dopplers Metabolic syncope: Hypoglycemia syncope, Hypoxia syncope, Shock, Hyperventilation, Anemia, Alcoholic Plan - Blood sugar QAC/HS - Continuous pulse-ox - Frequent vitals - CBC (iron studies if indicated) - Blood alcohol level; tox screen - Review medications (hypoglycemic dosing; sulfonylureas and insulin) Psychiatric: panic disorders, depression , hysteria ---------------------------------------------------------------------------------- # [C Difficle Diarrhea] Diagnosis of C difficile diarrhea: 3 or more unformed stools in 24 or fewer consecutive hours Positive test C. difficile and its toxins (conducted on unformed, diarrheal stool sample - only exception is suspected ileus). Treatment: Stop inciting antimicrobial therapy (all agents in the same class) ***. Avoid probiotic (lack of clinical data and the potential risk of blood stream infection) and antiperistaltic agents (might interfere with symptoms of infection; might increase the risk of toxic megacolon). @BRIEFLAB(WBC)@ ***> or <*** 15 @BRIEFLAB(creat)@ ***> or <*** 1.5xbaseline Cr of *** Treat with: If first episode, WBC<15 and Cr<1.5x baseline (mild-moderate disease) then Metronidazole 500 mg PO TID 10-14 days If first episode, WBC>15 or Cr>1.5x baseline (sever disease) then vancomycin 125mg QID PO 10-14 days If first episode with hypotension, shock, ileus or megacolon then vancomycin 500mg QID PO/NGT plus metronidazole 500 mg IV Q8h. Consider vancomycin per rectum with ileus or ostomy. First recurrence, treat same as first episode Second recurrence, use vancomycin PO in a tapered or pulsed regimen References: 1. Cohen SH et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31(5):000-000. 2. Gerding, DN et al. Treatment of Clostridium difficile Infection. Clin Infect Dis 2008; 46:S-32-42.
Result - Copy and paste this output:
Sandbox Metrics: Structured Data Index 0, 1384 boilerplate words
More SOAPnotes by this Author:
Send Feedback for this SOAPnote